{
  "$schema": "folio-library-entry/v1",
  "id": "10665-329296",
  "blocks": [
    {
      "id": "library/10665-329296/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 2,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "LE DIAGNOSTIC DU VIH ET \nL’UTILISATION DES ARV CHEZ \nLE NOURRISSON EXPOSÉ \nAU VIRUS: MISE A JOUR \nPROGRAMMATIQUE\nJUILLET 2018 \nRAPPORT TECHNIQUE",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The French-language cover of the July 2018 WHO technical report giving a programmatic update on HIV diagnosis and antiretroviral use in HIV-exposed infants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO/CDS/HIV/18.17",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/sec-000-whocdshiv1817.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "© Organisation mondiale de la Santé 2018",
      "pageStart": 2,
      "pageEnd": 3,
      "target": "../sections/sec-001-organisation-mondiale-de-la-santé-2018.md",
      "narrative": null,
      "content": "Certains droits réservés. La présente publication est disponible sous la licence Creative Commons \nAttribution - Pas d’utilisation commerciale - Partage dans les mêmes conditions 3.0 IGO (CC BY-NC-SA \n3.0 IGO ; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).\nAux termes de cette licence, vous pouvez copier, distribuer et adapter l’œuvre à des fins non \ncommerciales, pour autant que l’œuvre soit citée de manière appropriée, comme il est indiqué ci-\ndessous. Dans l’utilisation qui sera faite de l’œuvre, quelle qu’elle soit, il ne devra pas être suggéré que \nl’OMS approuve une organisation",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The French-language copyright and licence page of the 2018 WHO report on infant HIV diagnosis and ARV use, with Creative Commons terms, citation details and disclaimers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "RÉSUMÉ EXECUTIF",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/sec-002-11-résumé-executif.md",
      "narrative": null,
      "content": "Partout dans le monde, des enfants continuent d’être \ninfectés par le VIH et le diagnostic et le traitement des \nnourrissons et des enfants vivant avec le virus dans les \nmeilleurs délais reste toujours d’une importance critique. \nLa version 2016 des Lignes directrices unifiées de l’OMS \nsur l’utilisation des antirétroviraux pour le traitement \net la prévention de l’infection à VIH contenues dans le \ndocument 2016 WHO ARV Consolidated Guidelines on the \nUse of Antiretroviral Drugs for Treating and Preventing \nVIH Infection (ci-après Lignes directrices unifiées 2016 de \nl’OMS) présentent certai",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A French-language executive summary noting that children are still being infected with HIV and that the 2016 WHO consolidated ARV guidelines introduced approaches such as nucleic acid testing at birth. It explains that this update, following a 2018 Geneva meeting, describes changes in infant testing, prevention and treatment and emphasises a postnatal care package for exposed infants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ABRÉVIATIONS",
      "pageStart": 3,
      "pageEnd": 4,
      "target": "../sections/sec-003-abréviations.md",
      "narrative": null,
      "content": "3TC \t\nlamivudine \nADF\t\nassociation à dose fixe\nARV \t\nantirétroviraux\nAZT \t\nazidothymidine (zidovudine) \nCTX\t\ncotrimoxazole\nDPN\t\ndiagnostic précoce chez le nourrisson\nLPV/r \t lopinavir/ritonavir\nMON\t\nmode opératoire normalisé \nNVP \t\nnévirapine\nPCR \t\namplification génique\nPPNa\t\nprophylaxie postnatale améliorée\nPTME \t prévention de la transmission mère-enfant\nRAL \t\nraltégravir\nTAAN \t test d’amplification des acides nucléiques\nTAR\t\ntraitement antirétroviral\nTDR \t\ntest de diagnostic rapide\nTME \t\ntransmission mère-enfant\nVIH \t\nvirus de l’immunodéficience humaine",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A French-language list of abbreviations used in the report, such as those for antiretroviral drugs, early infant diagnosis and mother-to-child transmission.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-329296/blocks/figure-vfig-p004",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../figures/vfig-p004.webp",
      "narrative": "draft",
      "content": "Figure 1, a horizontal stacked bar chart (in French) of mother-to-child transmission rates in the 21 Start Free, Stay Free, AIDS Free priority countries (source: UNAIDS 2018 estimates), split into transmission during the first 6 weeks and after 6 weeks. Total rates range from 26% in Indonesia (19% + 7%) and Angola (15% + 11%) down to 5% in South Africa and Botswana. The render crops the left edge, truncating some country names and the surrounding text.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CONTEXTE",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-004-21-contexte.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Le Statu quo concernant l’infection à VIH chez le nourrisson et l’enfant",
      "pageStart": 4,
      "pageEnd": 5,
      "target": "../sections/sec-005-211-le-statu-quo-concernant-linfection-à-vih-che.md",
      "narrative": null,
      "content": "nourrisson et l’enfant\nL’initiative du Plan mondial pour éliminer les nouvelles infections \nà VIH chez les enfants à l’horizon 2015 et maintenir leur mères \nen vie a eu un impact considérable, conduisant à une réduction \nde 60% des nouveaux cas pédiatriques dans 21 pays à forte \ncharge d’infection à VIH en Afrique subsaharienne.1,2 Le nombre \ndes nouvelles infections à VIH chez l’enfant reste pourtant \nélevé: en 2017, 180 000 nouveaux cas pédiatriques ont été \nsignalés dans le monde, dont 70% dans les 21 pays prioritaires. \nLe cadre Start Free, Stay Free, AIDS Free3 a été mis sur pied pour \npo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the current situation of HIV among infants and children: the Global Plan sharply reduced new paediatric infections in priority sub-Saharan African countries, yet about 180 000 new child infections were reported in 2017, and the Start Free, Stay Free, AIDS Free framework was launched to carry progress forward towards ending AIDS by 2030. Wider antiretroviral therapy for pregnant women under Option B+ has lowered vertical transmission, but about half of new child infections now happen during breastfeeding, retaining women in care remains a challenge, and early infant diagnosis coverage is low, with a figure showing transmission rates by priority country. Only about half of children living with HIV were on treatment at the end of 2017, untreated infected infants face very high mortality, and suitable antiretroviral formulations for newborns and young infants remain scarce.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Justification de cette mise à jour technique",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/sec-006-212-justification-de-cette-mise-à-jour-technique.md",
      "narrative": null,
      "content": "Les Lignes directrices unifiées 2016 de l’OMS (2016 WHO \nARV Consolidated Guidelines on the Use of Antiretroviral \nDrugs for Treating and Preventing VIH Infection)10 ont \nprésenté des approches innovantes pour le diagnostic et le \ntraitement, Cependant, à ce jour seuls quelques pays ont \ncommencé à les mettre en œuvre. En outre, les données \nissues des premiers pays qui les ont adopté soulèvent de \nnombreux problèmes qui appellent à un examen attentif et \noffrent de nombreuses leçons apprises pour la planification \ndans les pays prévoyant d’adopter ces interventions. \n•\t La baisse des taux de",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the reasons for this technical update: few countries have yet implemented the 2016 WHO consolidated antiretroviral guidelines, and early adopters have raised issues such as more false-positive nucleic acid test results as transmission falls, delayed antibody development that complicates rapid tests in infants, operational barriers to testing at birth, difficulties with enhanced postnatal prophylaxis for high-risk infants, and the need for stronger postnatal care packages for exposed infants and their mothers. It notes that, after a WHO regional workshop in Johannesburg in June 2017, an expert meeting was held in April 2018, and that the update highlights the main changes and implementation considerations arising from the 2016 guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PRINCIPALES CONSIDÉRATIONS",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/sec-007-30-principales-considérations.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic chez le nourrisson",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/sec-008-31-diagnostic-chez-le-nourrisson.md",
      "narrative": null,
      "content": "La complexité du DPN augmente à la suite de l’extension \nmarquée de l’application de la politique qui vise à traiter tout \nle monde (y compris les femmes enceintes et allaitantes), \nde la mise en œuvre de la PPNa, de la diminution des taux \nde TME et du rôle proportionnellement plus important que \njoue la transmission postnatale. Le DPN ne peut plus être \nconsidéré avant tout comme fondé sur un seul test: des tests \nsupplémentaires sont désormais nécessaires sur la durée de \nl’exposition. Il faudra donc tenir compte de plusieurs autres \nconsidérations essentielles pour renforcer la chaîne des",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that early infant HIV diagnosis has grown more complex with treat-all policies, enhanced postnatal prophylaxis, lower transmission and the larger role of postnatal transmission, so testing must now continue throughout the exposure period without delaying treatment for infants found to be infected.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Réduire le nombre de résultats faux positifs en introduisant une fourchette indéterminée pour le DPN",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-009-311-réduire-le-nombre-de-résultats-faux-positifs.md",
      "narrative": null,
      "content": "introduisant une fourchette indéterminée pour le DPN \nSi le diagnostic chez le nourrisson est plus souvent pratiqué \nun peu partout grâce au meilleur accès au « traitement pour \ntout le monde », on assiste cependant à une augmentation \ndu nombre de faux positifs signalés dans les programmes \nà la suite de la baisse des taux de TME12 et de la faible \nvirémie observée chez les nourrissons dont l’infection à \nVIH est constatée.13 Certains nourrissons pourraient donc \nêtre diagnostiqués à tort comme infectés et inutilement \nmis sous TAR à vie. Aucune recommandation spécifique \nn’existe actuellemen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses how falling transmission rates and low viral levels in infected infants have increased false-positive early infant diagnosis results, so some infants may be wrongly started on lifelong treatment, while no guidance yet exists on what level counts as truly positive or on using an indeterminate range. Drawing on a systematic review of 32 studies and a follow-up study, it estimates that about 12.5% of non-negative initial results may be false positives where no indeterminate range is applied, and explains the choice of a cycle threshold of about 33 on a Roche assay as the optimal indeterminate cut-off, balancing missed infections against unnecessary treatment. It points to South Africa's and a new WHO standard operating procedure for handling indeterminate results and recommends retesting the original sample, which resolves most cases, before recalling the infant for a new specimen.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/figure-img-p006-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../images/img-p006-1.webp",
      "narrative": "draft",
      "content": "Photograph of a newborn baby wrapped in a white cloth, lying down with eyes partly open.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tests de confirmation de résultats positifs",
      "pageStart": 6,
      "pageEnd": 7,
      "target": "../sections/sec-010-312-tests-de-confirmation-de-résultats-positifs.md",
      "narrative": null,
      "content": "Une analyse du rapport coût-efficacité effectuée pour \ndéterminer la valeur d’un test de confirmation dans \ndifférents scénarios s’est révélée utile.16 En l’absence de \ntests de confirmation, cette analyse a démontré que dans \ndes situations où les taux de TME étaient semblables \nà ceux observés en Afrique du Sud, plus de 10% des \nnourrissons mis sous TAR pouvaient en réalité être non \ninfectés. Les tests de confirmation de résultats positifs sur \nun nouvel échantillon, conformément aux lignes directrices \nde l’OMS, permettraient d’éviter ces traitements inutiles, \nmême si cette politique n’es",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports a cost-effectiveness analysis showing that without confirmatory testing more than 10% of infants started on treatment could be uninfected where transmission is similar to South Africa, stresses retaining and testing all HIV-exposed infants and confirming every positive result, and includes a box defining diagnostic terms such as indeterminate range, false positives, false negatives, non-negative and discordant results, and cycle threshold. It concludes that, given new performance evidence and WHO prequalification of two point-of-care technologies, point-of-care early infant diagnosis may be used to confirm positive results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Gérer les résultats discordants et les interruptions de traitement",
      "pageStart": 7,
      "pageEnd": 8,
      "target": "../sections/sec-011-312-gérer-les-résultats-discordants-et-les-inter.md",
      "narrative": null,
      "content": "de traitement \nDepuis 2010, l’OMS recommande la mise sous TAR du nourrisson \naprès un TAAN initial positif, et le prélèvement simultané d’un \néchantillon de confirmation. Les Lignes directrices unifiées 2016 \nde l’OMS10 indiquent que si le deuxième TAAN (de confirmation) \nse révèle négatif, il y a lieu de procéder à un troisième TAAN, DPN \n(qualitatif) ou test de la charge virale, avant d’envisager l’arrêt \ndu TAR. L’introduction d’une fourchette indéterminée devrait \nréduire le nombre et la proportion des nourrissons présentant \ndes résultats discordants (résultats de TAAN différents sur \ndes",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses how to handle discordant infant HIV test results and when antiretroviral therapy may be stopped, listing conditions for interruption and for follow-up of infants whose treatment is halted. Describes South Africa's intensive 18-month monitoring policy and proposes a simpler option of qualitative and viral load testing at 4 weeks, 4 months and 8 months after interruption, with a return to treatment if any later test is positive. A box stresses prompt retesting of indeterminate results and priority confirmatory testing of all positive results until a final diagnosis is reached.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mise en œuvre du DPN sur le lieu des soins",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/sec-012-313-mise-en-œuvre-du-dpn-sur-le-lieu-des-soins.md",
      "narrative": null,
      "content": "Les Lignes directrices unifiées 2016 de l’OMS10 recommandent \nl’utilisation des technologies TAAN qui ont été élaborées et \nvalidées pour l’utilisation sur le lieu des soins ou à proximité pour \nle dépistage précoce du VIH chez le nourrisson. Le DPN sur le \nlieu des soins offre la possibilité de réduire les délais d’obtention \ndes résultats, de diminuer la perte de patients le long de la \nchaîne de dépistage du VIH, de réduire la mortalité infantile et \nde faciliter la réalisation de tâches par des agents subalternes \ndans un établissement de santé avec des services décentralisés. \nLes données",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that WHO's 2016 consolidated guidelines endorse nucleic acid tests validated for use at or near the point of care for early infant HIV diagnosis, citing studies in Malawi and Mozambique that showed faster results and quicker treatment start. Lists lessons from pilot projects, including site and product selection, maintenance arrangements, staff training, service linkages and the availability of paediatric antiretroviral formulations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction du TAAN à la naissance pour faciliter une mise sous traitement plus rapide",
      "pageStart": 8,
      "pageEnd": 9,
      "target": "../sections/sec-013-314-introduction-du-taan-à-la-naissance-pour-fac.md",
      "narrative": null,
      "content": "une mise sous traitement plus rapide \nL’adjonction du TAAN à la naissance dans le programme \nnational de dépistage du nourrisson pourrait permettre de \nrepérer plus rapidement les nouveau-nés infectés par le VIH \net donc de les mettre plus vite sous traitement et de diminuer \nles taux de mortalité infantile. Les données semblent montrer \nque les nourrissons testés positifs à la naissance sont mis \nsous TAR environ 2 mois avant ceux qui ne sont pas testés \nà la naissance (6 semaines au lieu de 15 semaines).23 Les \nanalyses du rapport coût/efficacité ont cependant montré \nque les gains en termes",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Examines adding nucleic acid testing at birth to national infant diagnosis programmes, noting that it can bring treatment forward by about two months but that survival gains vanish if too many infants testing negative at birth are lost to follow-up. Lists implementation considerations such as reviewing the existing 6-week programme, collecting data in pilots, targeting high-risk infants, actively tracing infants and returning results quickly. Boxes note that two point-of-care technologies are WHO-prequalified and describe South Africa's 2015 introduction of birth testing, which was well accepted but hampered by weak linkage to care and low return for later tests.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Kenya",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-014-kenya.md",
      "narrative": null,
      "content": "Le Kenya a introduit un projet pilote pour le TAAN à la \nnaissance en 2015 (défini comme un dépistage dans les 72 \nheures suivant la naissance) et les résultats de ce projet ont \nformé la base d’un algorithme révisé pour le DPN en 2016 et \nd’un plan national d’extension devant commencer au milieu de \n2018. Avant la mise en œuvre, un point central a été désigné \ndans l’établissement de santé pour le dépistage à la naissance, \nun registre novateur pour les envois a été mis au point, les \nmères ont bénéficié d’un mentorat pour faciliter les liens entre \nhôpitaux et communautés et un groupe de sou",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes Kenya's 2015 pilot of nucleic acid testing within 72 hours of birth, which informed a revised infant diagnosis algorithm in 2016 and a national scale-up plan due to begin in mid-2018. Preparations included a dedicated testing point, a new referral register, mentor mothers and a psychosocial support group, while problems involved referral, demand creation, result turnaround, uncollected results and a lack of newborn drug formulations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Zimbabwe",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-015-zimbabwe.md",
      "narrative": null,
      "content": "Le Zimbabwe a commencé son projet pilote de TAAN sur le \nlieu des soins pour des nourrissons à haut risque exposés au \nVIH (<48 heures après la naissance) en avril 2017 dans 10 \nétablissements de santé; 97% des résultats ont été transmis au \npersonnel soignant et tous les nourrissons infectés ont été mis \nsous TAR dans les 5 jours suivant le dépistage. Ce projet devrait \nfournir de précieuses données sur une approche différente \npour le suivi des nourrissons après le dépistage à la naissance, \net produire des informations supplémentaires sur la valeur d’un \ndépistage à la naissance ciblé sur l",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports on Zimbabwe's April 2017 pilot of point-of-care testing at birth for high-risk HIV-exposed infants in 10 facilities, where 97% of results reached caregivers and all infected infants began treatment within 5 days.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "République démocratique du Congo",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-016-république-démocratique-du-congo.md",
      "narrative": null,
      "content": "Le TAAN à la naissance a été mis en œuvre pour la première \nfois en décembre 2016, avec des échantillons envoyés \naux laboratoires centraux pour analyse. Le personnel \nde laboratoire a été formé pour donner la priorité aux \néchantillons prélevés à la naissance et pour veiller au retour \nrapide des résultats à l’établissement de santé concerné. Les \ndifficultés rencontrées ont notamment concerné: les longs \ndélais entre la collecte des échantillons et la réception des \nrésultats (8-12 semaines depuis le laboratoire national), les \nruptures de stocks liées aux limitations dans la gestion de \nla",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the Democratic Republic of the Congo's birth-testing pilot started in December 2016, with samples sent to central laboratories whose staff were trained to prioritise them. Long turnaround times of 8–12 weeks, stock-outs, sample transport problems and the early discharge of mothers limited the pilot, which has ended while the country strengthens its 6-week infant testing programme.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Eswatini",
      "pageStart": 9,
      "pageEnd": 11,
      "target": "../sections/sec-017-eswatini.md",
      "narrative": null,
      "content": "L’Eswatini a introduit deux projets pilotes de TAAN à la \nnaissance sur 5 sites de maternité en août 2017, faisant appel \naux technologies de DPN sur le lieu des soins dans trois sites \n(en partenariat avec EGPAF) et au dépistage conventionnel \ndans deux sites (en partenariat avec ICAP). Dans le projet pilote \nconventionnel, 93% des nouveau-nés exposés au VIH ont été \ntestés avant de quitter la maternité et 6 sur les 1548 testés se \nsont révélés infectés. Dans le projet pilote de dépistage sur le \nlieu des soins, 68% des nouveau-nés exposés au VIH ont été \ntestés et 12 sur 1314 se sont révélés",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports on Eswatini's two birth-testing pilots begun in August 2017 at five maternity sites, comparing point-of-care and conventional testing in terms of coverage, infections detected and treatment started. Both pilots showed added workload for nurses, missed tests as mothers left early or gave wrong contact details, and follow-up difficulties, and the block ends with further considerations on linking infants to treatment and on quality coordination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/figure-img-p010-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../images/img-p010-1.webp",
      "narrative": "draft",
      "content": "Photograph of a smiling infant girl in a yellow top leaning on the knee of an adult, against a reddish earth background.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Assurer une interprétation correcte du test à 9 mois et simplifier l’algorithme de dépistage",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-018-315-assurer-une-interprétation-correcte-du-test.md",
      "narrative": null,
      "content": "à 9 mois et simplifier l’algorithme de dépistage \nLes Lignes directrices unifiées 2016 de l’OMS recommandent \nde recourir au TDR pour évaluer l’exposition au VIH du \nnourrisson âgé de moins de 4 mois, alors que l’exposition \nentre 4 et 18 mois doit être vérifiée au moyen d’un dépistage \nchez la mère. Si celui-ci n’est pas possible, les lignes \ndirectrices actuelles soulignent qu’il est important de ne pas \nconsidérer un résultat négatif du TDR chez un enfant âgé de \n4 à 18 mois comme un résultat définitif. Les considérations \nrelatives à la mise en œuvre sont traitées dans l’Encadré 5.\nSur la",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that changing transmission dynamics, greater antiretroviral exposure and late maternal infection make the rapid diagnostic test at 9 months increasingly unreliable for ruling out infant HIV infection, citing findings from Uganda and Kenya. Proposes replacing it with a nucleic acid test at 9 months for all HIV-exposed infants and summarises the principles of the simplified algorithm in Annex 3, including maternal testing to establish exposure, confirmatory testing and regular follow-up until final diagnosis. A box sets out implementation considerations for rapid tests, such as prioritising maternal testing and not treating a negative infant result after 4 months as final.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Utilisation des ARV pour la prévention et le traitement de l’infection à VIH chez le nourrisson",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-019-32-utilisation-des-arv-pour-la-prévention-et-le.md",
      "narrative": null,
      "content": "et le traitement de l’infection à VIH chez \nle nourrisson",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment of a section heading on the use of antiretrovirals to prevent and treat HIV infection in infants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Defis de mise en œuvre d’une PPNa chez le nourrisson à haut risque",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-020-321-defis-de-mise-en-œuvre-dune-ppna-chez-le-nou.md",
      "narrative": null,
      "content": "nourrisson à haut risque\nLes Lignes directrices unifiées 2016 de l’OMS recommandent \nun traitement associant l’AZT et la NVP qui peut être \nprolongé jusqu’à 12 semaines chez le nourrisson allaité par \nla mère et fortement exposé au risque de TME. Est considéré \ncomme sujet à haut risque, le nourrisson dont la mère a été \nidentifiée VIH positive pour la première fois au moment de \nl’accouchement ou lors du postpartum, ou infectée pendant \nla grossesse ou la période d’allaitement, a commencé un \ntraitement ARV en fin de grossesse ou chez qui la suppression \nde la charge virale n’était pas interv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out WHO's 2016 recommendation of AZT plus NVP prophylaxis for up to 12 weeks for breastfed infants at high risk of HIV transmission, defines high risk and describes how different countries have adopted enhanced postnatal prophylaxis. Notes that giving it to all exposed infants raises cost and toxicity and should only be a temporary measure, and discusses situations where maternal viral suppression cannot be assured and prophylaxis might be extended. Raises the option of presumptive triple-drug treatment for infants of mothers diagnosed late or newly infected, with attention to its effect on infant testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Traitement précoce du nourrisson: options limitées et complexité de l’administration",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-021-322-traitement-précoce-du-nourrisson-options-lim.md",
      "narrative": null,
      "content": "et complexité de l’administration\nUn TAR précoce chez le nourrisson permet d’améliorer la survie \net de réduire la morbidité à long terme, mais la mortalité reste \nforte au cours des premiers mois. L’introduction du TAAN à \nla naissance pourrait permettre de commencer le TAR avant \nl’âge de deux semaines. Or le seul traitement dont on dispose \nà cet âge contient depuis de nombreuses années l’association \nAZT/3TC/NVP. Ce traitement pourrait être maintenu avec un \nsuivi clinique attentif jusqu’à trois mois et remplacé ensuite par \nun schéma thérapeutique à base de LPV/r fondé sur des pellets \nde",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses early antiretroviral treatment for infants diagnosed at birth, noting that it improves survival but early mortality stays high and treatment options at that age are limited, for example AZT/3TC/NVP until three months followed by an LPV/r-based regimen, and reports the recent US FDA approval of raltegravir granules for term newborns of normal weight. It advises countries planning birth testing to consider decentralizing newborn treatment by building health worker skills, securing supplies in peripheral facilities and extending referral links. A box on drug formulations for infant postnatal prophylaxis compares syrups, dispersible tablets and paediatric fixed-dose combinations, setting out the dosing problems and unwanted 3TC exposure of the AZT/3TC/NVP combination despite its wide availability.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/figure-img-p014-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../images/img-p014-1.webp",
      "narrative": "draft",
      "content": "Photograph of a gloved health worker collecting blood from an infant's heel onto a dried blood spot card while a woman holds the infant.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Améliorer la prestation des services et mettre en place un module de soins postnatals",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-022-33-améliorer-la-prestation-des-services-et-mettr.md",
      "narrative": null,
      "content": "et mettre en place un module de soins \npostnatals\nPour mettre en place des services efficaces contre le VIH pour \nle nourrisson, différents obstacles doivent être surmontés \net aucune intervention ne permet à elle seule de régler tous \nles problèmes auxquels la mère et le nourrisson se trouvent \nconfrontés à différents moments et dans des situations diverses. \nLes facteurs socioéconomiques et traditionnels assurant le \nmaintien du couple mère-enfant figurent parmi les conditions \npropres à favoriser l’utilisation des services. Il serait utile \nd’associer dans les programmes plusieurs intervent",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Argues that effective HIV services for infants need a package combining several interventions rather than any single one, citing proven client-focused measures such as text-message reminders, financial incentives and involving male partners, and system-focused measures such as point-of-care testing, provider training and support, peer support and quality improvement. It stresses integrating HIV care into maternal, newborn and child health platforms and joint information systems so that mother–infant pairs stay in care until a final diagnosis, while noting the added workload for those services. It also highlights community engagement, including networks of women living with HIV, in reducing loss to follow-up, and ends with the heading of a box on key research priorities.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic chez le nourrisson",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-023-diagnostic-chez-le-nourrisson.md",
      "narrative": null,
      "content": "•\t \tÉvaluer l’impact de la mise en œuvre d’une fourchette \nd’indétermination, surtout pour les tests effectués \nà différents moments et pour différents types \nd’échantillons et technologies.\n•\t Obtenir des données d’impact pour déterminer la \nvaleur ajoutée du dépistage à la naissance dans le \ncadre du programme DPN.\n•\t Évaluer l’utilité d’un dépistage à la naissance limité \naux seuls nourrissons à haut risque.\n•\t Mesurer l’impact des outils de suivi (comme les \ncodes-barres) pour assurer un suivi efficace et refaire \nle dépistage à six semaines chez le nourrisson dont le \ntest à la naissance",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists research priorities on infant HIV diagnosis, including the impact of an indeterminate range, the added value of birth testing and of limiting it to high-risk infants, and tracking tools such as barcodes. Further items cover combining birth testing with BCG vaccination, the timing of viral load testing in pregnant and breastfeeding women, the effect of maternal treatment and infant prophylaxis on diagnosis, and ways to retain infants until final diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Prophylaxie et traitement du nourrisson",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-024-prophylaxie-et-traitement-du-nourrisson.md",
      "narrative": null,
      "content": "•\t Déterminer la posologie et l’innocuité des nouveaux \nARV destinés à la prophylaxie ou au traitement du \nnouveau-né et du nourrisson.\n•\t Mettre au point des formes galéniques optimales et \nassurer l’introduction en temps opportun des ARV \nnouvellement recommandés pour le nouveau-né et \nle nourrisson.\n•\t Réunir des données sur les expériences des pays en \nmatière de PPNa.\n•\t Comprendre la pertinence clinique des épisodes \nvirémiques maternels et leur contribution relative au \ntaux de transmission global.\n•\t Mener des études pour déterminer les avantages \nsupplémentaires apportés par la PPNa d",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists research priorities on infant prophylaxis and treatment, such as the dosing and safety of new antiretrovirals for newborns, better formulations, country experience of and adherence to enhanced prophylaxis, and the feasibility of triple-drug prophylaxis when the mother is diagnosed after delivery.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Prestation de services et module de soins postnatals",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-025-prestation-de-services-et-module-de-soins-postna.md",
      "narrative": null,
      "content": "•\t Envisager d’associer plusieurs interventions dans le cadre \nd’un module visant à appuyer la prestation de services.\n•\t Promouvoir l’intégration pour faire en sorte que le \nnourrisson reste dans la chaîne de dépistage jusqu’au \ndiagnostic final.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists two action points for service delivery: combining interventions in a package and promoting integration so that infants stay in testing until final diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "RÉCAPITULATIF ET MESURES À PRENDRE",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-026-4-récapitulatif-et-mesures-à-prendre.md",
      "narrative": null,
      "content": "Plusieurs innovations inédites mises en œuvre par les pays \net les partenaires ont montré des résultats prometteurs. \nPendant que des interventions probantes sont reprises plus \nlargement, il reste essentiel de privilégier le renforcement \ndes systèmes existants qui appuient le dépistage du \nnourrisson et le traitement précoce. De plus, l’évolution de \nla dynamique des normes de transmission et de traitement \najoute à la complexité et à l’interdépendance des tests, de \nla prophylaxie et du traitement. Cela nécessitera un besoin \ncroissant d’adapter les stratégies au contexte épidémique \net pol",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises that promising innovations should be scaled up while existing infant testing and early treatment systems remain the priority, with strategies adapted to changing contexts and more evidence built to guide national policy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/figure-img-p016-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../images/img-p016-1.webp",
      "narrative": "draft",
      "content": "Photograph of a group of women in colourful head wraps, some carrying infants, standing outdoors in a village with men in the background.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REMERCIEMENTS",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-027-remerciements.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Participants à la réunion",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-028-participants-à-la-réunion.md",
      "narrative": null,
      "content": "Adolfo Vubil (INS Mozambique), Ahmed Haeri Mazanderai \n(University of Pretoria), Andrea Ciaranello (Harvard \nMedical School), Angela Mushavi (Ministère de la \nsanté, Zimbabwe), Anna Laura Ross (Unitaid), Archawin \nRojanawiwat (Université Chulalongkorn), Arne Kroidl \n(Université de Munich), Charles Kiyaga (Ministère de la \nsanté, Ouganda), David Sullivan (USAID), Debbie Boras \n(London School of Hygiene and Tropical Medicine), \nDeborah Persaud (Johns Hopkins University), Elaine \nAbrams (ICAP), George Siberry (OGAC), Heather Alexander \n(CDC), Helen Dale (US CDC), Jean Maritz (University of \nStell",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the meeting participants and their institutional affiliations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Membres du personnel de l’OMS",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-029-membres-du-personnel-de-loms.md",
      "narrative": null,
      "content": "Meg Doherty, Martina Penazzato, Lara Vojnov, Anisa \nGhadrshenas, Serena Brusamento, Morkor Newman, \nMercedes Perez, Fatim Jallow.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the WHO staff members who contributed to the document.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "RÉFÉRENCES BIBLIOGRAPHIQUES",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-030-références-bibliographiques.md",
      "narrative": null,
      "content": "BIBLIOGRAPHIQUES\n1.\t UNAIDS. On the Fast-track to an AIDS-Free Generation. \nGeneva: UNAIDS; 2016. \n2.\t ONUSIDA. Plan mondial pour éliminer les nouvelles \ninfections à VIH chez les enfants à l’horizon 2015 et \nmaintenir leurs mères en vie. Genève, ONUSIDA, 2016. \n3.\t UNAIDS. Start free Stay free AIDS free: 2017 progress \nreport. UNAIDS; 2017. \n4.\t OMS. Lignes directrices unifiées sur l’utilisation des \nantirétroviraux pour le traitement et la prévention de \nl’infection à VIH. Genève, OMS, 2013.\n5.\t Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de \nRuiter A, Lyall H, et al. Earlier initiation",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list of a WHO document on HIV diagnosis and care in infants, followed by stray fragments of a testing algorithm flowchart.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ANNEXES",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-031-annexes.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexe 1: Mode opératoire normalisé à suivre pour les résultats indéterminés",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-032-annexe-1-mode-opératoire-normalisé-à-suivre-pour.md",
      "narrative": null,
      "content": "1. Voir les Lignes directrices unifiées 2016 de l’OMS (2016 WHO ARV Consolidated Guidelines).\n2. Ne pas notifier comme positif et ne pas commencer le TAR, mais poursuivre la prophylaxie selon les lignes directrices actuelles. \n3. Le laboratoire traitera en priorité les nouveaux échantillons demandés.\n4. \u0007En cas de résultats à nouveau indéterminés sur deux échantillons distincts, ces résultats et les informations cliniques seront \nsoumis à une équipe de laboratoires, de pédiatres cliniciens, d’experts de cas complexes (si possible), et le personnel soignant. \nLes nourrissons devront faire l’obj",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the footnotes to the standard operating procedure for indeterminate results, advising against reporting them as positive or starting treatment, prioritising new samples, and referring repeated indeterminate results to a multidisciplinary team with active follow-up of infants.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexe 2: Procédure à suivre en cas de résultats discordants et d’interruption d’un traitement",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-033-annexe-2-procédure-à-suivre-en-cas-de-résultats.md",
      "narrative": null,
      "content": "Cette option prévoit des soins de suivi du nourrisson \npendant au moins 8 mois après l’interruption d’un TAR.  \nIl convient si possible de procéder à un test DPN (qualitatif) \net de la charge virale (quantitatif) 4 semaines, 4 mois et \n8 mois après l’interruption du traitement.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes an option for following up infants for at least 8 months after stopping treatment, with qualitative and viral load testing at 4 weeks, 4 months and 8 months.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "DPN et charge virale 4 semaines, 4 mois et 8 mois après l’interruption",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-034-dpn-et-charge-virale-4-semaines-4-mois-et-8-mois.md",
      "narrative": null,
      "content": "Scénario a: L’arrêt de l’allaitement maternel survient après la fin du suivi post interruption du TAR.\nScénario b: L’arrêt de l’allaitement maternel survient avant la fin du suivi post interruption du TAR.\n8 mois",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the two scenarios in the Annex 2 diagram, depending on whether breastfeeding stops after or before the end of follow-up following treatment interruption.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TAAN 1: +",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-035-taan-1.md",
      "narrative": null,
      "content": "début TAR\nDébut de l’interruption \ndu traitement\nTAAN 4 semaines \naprès l’interruption\nTAAN 4 mois \naprès l’interruption\nTAAN 8 mois \naprès l’interruption\nTAAN 1\nTAAN 2",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Fragmentary diagram labels showing the timeline of nucleic acid tests at 4 weeks, 4 months and 8 months after treatment interruption.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TAAN 2: -",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-036-taan-2.md",
      "narrative": null,
      "content": "maintien TAR",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A single diagram label indicating that antiretroviral therapy is continued.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TAAN 3: -",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-037-taan-3.md",
      "narrative": null,
      "content": "arrêt TAR\nTAAN 3\nArrêt de l’allaitement \nmaternel\nTDR 3 mois après \nl’arrêt de \nl’allaitement \nmaternel\nDébut de l’interruption \ndu traitement\nTAAN 4 semaines \naprès l’interruption\nTAAN 4 mois \naprès l’interruption\nTAAN 8 mois \naprès l’interruption\nTAAN 1\nTAAN 2\nTAAN 3\nArrêt de l’allaitement maternel\n8 mois\nTAAN 1: +\ndébut TAR\nTAAN 2: -\nmaintien TAR\nTAAN 3: -\narrêt TAR\nUn suivi ultérieur est nécessaire pour envisager l’exposition \nà l’allaitement maternel et respecter le programme national \nde dépistage chez le nourrisson exposé au VIH pour assurer \nun diagnostic final approprié. Si l’arrêt de",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Diagram labels for the treatment-interruption timeline, followed by a note that further follow-up accounting for breastfeeding is needed and that, if breastfeeding stops early, final status can be set by a nucleic acid test at least 6 weeks after it ends.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexe 3: Algorithme simplifié pour le DPN",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-038-annexe-3-algorithme-simplifié-pour-le-dpn.md",
      "narrative": null,
      "content": "Nouveau-né exposé au VIH (0 à 2 jours)\nEnvisager un TAANa,b\nNégatif\nNégatif\nCommencer \nimmédiatement le TARc\nSuivi clinique régulier\nLe nourrisson/l’enfant est infecté\nNourrisson ou enfant exposé au VIH \n(de 4-6 semaines à 18 mois)\nProcéder à un TAANb \n(à 4-6 semaines ou le plus tôt \npossible ultérieurement)\nPositif\nPositif\nCommencer \nimmédiatement le TARc\nRefaire un TAAN pour \nconfirmer l’infection\nL’infection par le VIH n’est pas détectée \nmais en cas d’allaitement maternel \nle risque d’infection subsiste jusqu’à \nl’arrêt complet de l’allaitementd \nRefaire un TAAN pour confirmer l’infection",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the simplified infant HIV diagnosis algorithm as flowchart text, from optional testing at birth through nucleic acid tests at 4–6 weeks and 9 months to antibody testing at 18 months or 3 months after breastfeeding ends. Lists the key principles for determining infection in HIV-exposed children under 18 months in low- and middle-income countries, including testing symptomatic children, confirmatory testing and regular follow-up with cotrimoxazole prophylaxis. Footnotes explain point-of-care use, immediate treatment with parallel confirmation, and how breastfeeding affects the timing of the final diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexe 4: Algorithme pour l’évaluation du risque d’infection",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-039-annexe-4-algorithme-pour-lévaluation-du-risque-d.md",
      "narrative": null,
      "content": "Cet algorithme a été établi pour faciliter l’évaluation du risque au moment de l’accouchement et le l’identification \ndes nourrissons à haut et à faible risque d’infection:\nLe nourrisson à faible risque doit recevoir une prophylaxie \nstandard (NVP ou AZT seule pour 4-6 semaines) tandis que \nle nourrisson à haut risque doit bénéficier d’une PPNa. Pour \nbien utiliser cet algorithme, le clinicien devra connaître un \ncertain nombre de paramètres figurant sur la fiche prénatale \nde la mère: \n•\t statut sérologique et date du dernier test de dépistage \n(afin de déterminer le statut et d’évaluer la né",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces an algorithm for assessing infant HIV risk at delivery, so that low-risk infants receive standard prophylaxis and high-risk infants receive enhanced postnatal prophylaxis. Lists the maternal information clinicians need, recommends viral load testing around week 36 of pregnancy, and includes fragmentary flowchart labels classifying risk.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "La mère a-t-elle été sous TAR pendant >4 semaines avant l’accouchement",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-040-la-mère-a-t-elle-été-sous-tar-pendant-4-semaines.md",
      "narrative": null,
      "content": "pendant >4 semaines avant \nl’accouchement\nOUI \n< 1,000\nOUI \n> 1,000\nStatut sérologique de la mère AU MOMENT DE L’ACCOUCHEMENT",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Fragmentary flowchart labels on maternal HIV status at delivery, time on treatment before delivery, and viral load above or below 1,000.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Connaît-on la charge virale moins de",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-041-connaît-on-la-charge-virale-moins-de.md",
      "narrative": null,
      "content": "4 semaines avant l’accouchement?",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment of a flowchart question asking whether the viral load is known from within 4 weeks before delivery.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexe 5: Posologie et formes galéniques pour la prophylaxie chez le nourrisson",
      "pageStart": 22,
      "pageEnd": 24,
      "target": "../sections/sec-042-annexe-5-posologie-et-formes-galéniques-pour-la.md",
      "narrative": null,
      "content": "Forme \ngalénique\nPosologie  \n0-6 semaines \nAZT plus NVP\nPosologie  \n6-12 semaines \nAZT plus NVP\nPosologie  \n6-12 semaines \nNVP seule\nObservations\nSirops \nAZT 10mg/\nml\nNVP 10mg/\nml\n1,5 ml (15 mg) \nd’AZT deux fois \npar jour\n6 ml (60 mg) d’AZT \ndeux fois par jour\n2 ml (20 mg)  \nde NVP une fois \npar jour\n- Dosage précis de tous les produits (y compris en cas \nd’insuffisance pondérale à la naissance) et une même \nforme galénique pour les 12 semaines\n- L’achat et le transport des sirops est coûteux\n- Difficile à dissimuler à domicile\n- Disponibilité parfois limitée chez le fournisseur\n- Solution pou",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Tabulates doses and formulations for enhanced postnatal prophylaxis (syrups, single-drug tablets and fixed-dose combinations) for weeks 0–6 and 6–12, with the advantages and drawbacks of each. Notes that AZT has no separate prophylactic dose and that presumptive treatment should follow age-based dosing, and ends with contact details for WHO's HIV/AIDS department and the document number WHO/CDS/HIV/18.17.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-329296/blocks/figure-img-p023-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../images/img-p023-1.webp",
      "narrative": "draft",
      "content": "Photograph of an infant in a red top resting on the shoulder of a woman wearing an orange veil.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
